<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated 16 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> with 24 courses of bolus topotecan </plain></SENT>
<SENT sid="1" pm="."><plain>Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d) </plain></SENT>
<SENT sid="2" pm="."><plain>There was one complete response and one partial response (overall response rate 12%) </plain></SENT>
<SENT sid="3" pm="."><plain>Toxicity included <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, <z:hpo ids='HP_0002595'>ileus</z:hpo> and mucositis </plain></SENT>
<SENT sid="4" pm="."><plain>There were 3 treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>